Telmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRN |
Texto Completo: | https://repositorio.ufrn.br/handle/123456789/46194 |
Resumo: | Background: Telmisartan is an antihypertensive angiotensin II receptor blocker. This antihypertensive shows antiinflammatory activity. Purpose: In this study, the antiinflammatory activity of telmisartan was tested in an acetic acid (10%) model of ulcerative colitis (UC) in rats. Methods: Rats were given 1, 3, and 5 mg/kg/day of telmisartan orally for 3 days before induction of UC. The same doses were also administered 2 and 24 h after induction. Rats from the non-colitis and non- treated colitis groups were administered vehicle (saline, 5 ml/kg) orally and another group received sulfasalazine (50 mg/kg/day). Colons tissue was analyzed by macroscopic, by histopathology, by the immunohistochemical examination of RANKL/RANK pathway; by ELISA analysis of the levels of IL-10, TNF-a, myeloperoxidase (MPO) and malonaldehyde (MDA). Results: Telmisartan at 5 mg/kg reduced levels of MPO, MDA, TNF-a and increased of IL-10 (p < 0.05). Additionally, telmisartan reduced macroscopic damage, number of ulcers, and inflammatory and histopathological processes such as neutrophil infiltration, changes in cytoarchitecture, and necrosis. Immunohistochemistry revealed down-regulation of nuclear factor-kappaB receptor/nuclear factor- kappaB ligand (RANK/RANKL) in groups treated with sulfasalazine or telmisartan. Conclusion: Telmisartan exerts beneficial effects in an acetic acid model of colitis in rats. These effects may be due to accelerated termination of the acute inflammatory phase, indicated by decreased TNF-a and increased production of IL-10 and low expression of RANKL and RANK. 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. |
id |
UFRN_036d51098eb3694703b06bc6bc43fe2c |
---|---|
oai_identifier_str |
oai:https://repositorio.ufrn.br:123456789/46194 |
network_acronym_str |
UFRN |
network_name_str |
Repositório Institucional da UFRN |
repository_id_str |
|
spelling |
Silva, Késia Karina de Oliveira SoutoGuerra, Gerlane Coelho BernardoAraujo, Aurigena Antunes deLira, George A.Melo, Maryanne N.Fernandes, DalineSilva, Arthur L.Araujo Junior, Raimundo Fernandes de2022-02-22T19:34:27Z2022-02-22T19:34:27Z2015-06GUERRA, Gerlane C. B.; ARAÚJO, Aurigena A.; LIRA, George A.; MELO, Maryanne N.; SOUTO, Késia K. O.; FERNANDES, Daline; SILVA, Arthur L.; ARAÚJO JÚNIOR, Raimundo F.. Telmisartan decreases inflammation by modulating TNF-α, IL-10, and RANK/RANKL in a rat model of ulcerative colitis. Pharmacological Reports, [S. l.], v. 67, n. 3, p. 520-526, jun. 2015. Springer Science and Business Media LLC. DOI: http://dx.doi.org/10.1016/j.pharep.2014.12.011. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S173411401400382X?via%3Dihub. Acesso em: 11 abr. 2021.Electronic: 1734-1140https://repositorio.ufrn.br/handle/123456789/46194org/10.1016/j.pharep.2014.12.011Pharmacological ReportsAttribution 3.0 Brazilhttp://creativecommons.org/licenses/by/3.0/br/info:eu-repo/semantics/openAccessangiotensin II receptor blockersantiinflammatoryimmunohistochemicalratsTelmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleBackground: Telmisartan is an antihypertensive angiotensin II receptor blocker. This antihypertensive shows antiinflammatory activity. Purpose: In this study, the antiinflammatory activity of telmisartan was tested in an acetic acid (10%) model of ulcerative colitis (UC) in rats. Methods: Rats were given 1, 3, and 5 mg/kg/day of telmisartan orally for 3 days before induction of UC. The same doses were also administered 2 and 24 h after induction. Rats from the non-colitis and non- treated colitis groups were administered vehicle (saline, 5 ml/kg) orally and another group received sulfasalazine (50 mg/kg/day). Colons tissue was analyzed by macroscopic, by histopathology, by the immunohistochemical examination of RANKL/RANK pathway; by ELISA analysis of the levels of IL-10, TNF-a, myeloperoxidase (MPO) and malonaldehyde (MDA). Results: Telmisartan at 5 mg/kg reduced levels of MPO, MDA, TNF-a and increased of IL-10 (p < 0.05). Additionally, telmisartan reduced macroscopic damage, number of ulcers, and inflammatory and histopathological processes such as neutrophil infiltration, changes in cytoarchitecture, and necrosis. Immunohistochemistry revealed down-regulation of nuclear factor-kappaB receptor/nuclear factor- kappaB ligand (RANK/RANKL) in groups treated with sulfasalazine or telmisartan. Conclusion: Telmisartan exerts beneficial effects in an acetic acid model of colitis in rats. These effects may be due to accelerated termination of the acute inflammatory phase, indicated by decreased TNF-a and increased production of IL-10 and low expression of RANKL and RANK. 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp.engreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNORIGINALTelmisartanDecreasesInflammation_SILVA_2015.pdfTelmisartanDecreasesInflammation_SILVA_2015.pdfapplication/pdf3377604https://repositorio.ufrn.br/bitstream/123456789/46194/1/TelmisartanDecreasesInflammation_SILVA_2015.pdfc7fd9496d72864eab4606db506b67a3cMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8914https://repositorio.ufrn.br/bitstream/123456789/46194/2/license_rdf4d2950bda3d176f570a9f8b328dfbbefMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81484https://repositorio.ufrn.br/bitstream/123456789/46194/3/license.txte9597aa2854d128fd968be5edc8a28d9MD53123456789/461942022-02-22 16:34:27.732oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2022-02-22T19:34:27Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false |
dc.title.pt_BR.fl_str_mv |
Telmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitis |
title |
Telmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitis |
spellingShingle |
Telmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitis Silva, Késia Karina de Oliveira Souto angiotensin II receptor blockers antiinflammatory immunohistochemical rats |
title_short |
Telmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitis |
title_full |
Telmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitis |
title_fullStr |
Telmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitis |
title_full_unstemmed |
Telmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitis |
title_sort |
Telmisartan decreases inflammation by modulating TNF-a, IL-10, and RANK/RANKL in a rat model of ulcerative colitis |
author |
Silva, Késia Karina de Oliveira Souto |
author_facet |
Silva, Késia Karina de Oliveira Souto Guerra, Gerlane Coelho Bernardo Araujo, Aurigena Antunes de Lira, George A. Melo, Maryanne N. Fernandes, Daline Silva, Arthur L. Araujo Junior, Raimundo Fernandes de |
author_role |
author |
author2 |
Guerra, Gerlane Coelho Bernardo Araujo, Aurigena Antunes de Lira, George A. Melo, Maryanne N. Fernandes, Daline Silva, Arthur L. Araujo Junior, Raimundo Fernandes de |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Silva, Késia Karina de Oliveira Souto Guerra, Gerlane Coelho Bernardo Araujo, Aurigena Antunes de Lira, George A. Melo, Maryanne N. Fernandes, Daline Silva, Arthur L. Araujo Junior, Raimundo Fernandes de |
dc.subject.por.fl_str_mv |
angiotensin II receptor blockers antiinflammatory immunohistochemical rats |
topic |
angiotensin II receptor blockers antiinflammatory immunohistochemical rats |
description |
Background: Telmisartan is an antihypertensive angiotensin II receptor blocker. This antihypertensive shows antiinflammatory activity. Purpose: In this study, the antiinflammatory activity of telmisartan was tested in an acetic acid (10%) model of ulcerative colitis (UC) in rats. Methods: Rats were given 1, 3, and 5 mg/kg/day of telmisartan orally for 3 days before induction of UC. The same doses were also administered 2 and 24 h after induction. Rats from the non-colitis and non- treated colitis groups were administered vehicle (saline, 5 ml/kg) orally and another group received sulfasalazine (50 mg/kg/day). Colons tissue was analyzed by macroscopic, by histopathology, by the immunohistochemical examination of RANKL/RANK pathway; by ELISA analysis of the levels of IL-10, TNF-a, myeloperoxidase (MPO) and malonaldehyde (MDA). Results: Telmisartan at 5 mg/kg reduced levels of MPO, MDA, TNF-a and increased of IL-10 (p < 0.05). Additionally, telmisartan reduced macroscopic damage, number of ulcers, and inflammatory and histopathological processes such as neutrophil infiltration, changes in cytoarchitecture, and necrosis. Immunohistochemistry revealed down-regulation of nuclear factor-kappaB receptor/nuclear factor- kappaB ligand (RANK/RANKL) in groups treated with sulfasalazine or telmisartan. Conclusion: Telmisartan exerts beneficial effects in an acetic acid model of colitis in rats. These effects may be due to accelerated termination of the acute inflammatory phase, indicated by decreased TNF-a and increased production of IL-10 and low expression of RANKL and RANK. 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. |
publishDate |
2015 |
dc.date.issued.fl_str_mv |
2015-06 |
dc.date.accessioned.fl_str_mv |
2022-02-22T19:34:27Z |
dc.date.available.fl_str_mv |
2022-02-22T19:34:27Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
GUERRA, Gerlane C. B.; ARAÚJO, Aurigena A.; LIRA, George A.; MELO, Maryanne N.; SOUTO, Késia K. O.; FERNANDES, Daline; SILVA, Arthur L.; ARAÚJO JÚNIOR, Raimundo F.. Telmisartan decreases inflammation by modulating TNF-α, IL-10, and RANK/RANKL in a rat model of ulcerative colitis. Pharmacological Reports, [S. l.], v. 67, n. 3, p. 520-526, jun. 2015. Springer Science and Business Media LLC. DOI: http://dx.doi.org/10.1016/j.pharep.2014.12.011. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S173411401400382X?via%3Dihub. Acesso em: 11 abr. 2021. |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufrn.br/handle/123456789/46194 |
dc.identifier.issn.none.fl_str_mv |
Electronic: 1734-1140 |
dc.identifier.doi.none.fl_str_mv |
org/10.1016/j.pharep.2014.12.011 |
identifier_str_mv |
GUERRA, Gerlane C. B.; ARAÚJO, Aurigena A.; LIRA, George A.; MELO, Maryanne N.; SOUTO, Késia K. O.; FERNANDES, Daline; SILVA, Arthur L.; ARAÚJO JÚNIOR, Raimundo F.. Telmisartan decreases inflammation by modulating TNF-α, IL-10, and RANK/RANKL in a rat model of ulcerative colitis. Pharmacological Reports, [S. l.], v. 67, n. 3, p. 520-526, jun. 2015. Springer Science and Business Media LLC. DOI: http://dx.doi.org/10.1016/j.pharep.2014.12.011. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S173411401400382X?via%3Dihub. Acesso em: 11 abr. 2021. Electronic: 1734-1140 org/10.1016/j.pharep.2014.12.011 |
url |
https://repositorio.ufrn.br/handle/123456789/46194 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
Attribution 3.0 Brazil http://creativecommons.org/licenses/by/3.0/br/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution 3.0 Brazil http://creativecommons.org/licenses/by/3.0/br/ |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Pharmacological Reports |
publisher.none.fl_str_mv |
Pharmacological Reports |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRN instname:Universidade Federal do Rio Grande do Norte (UFRN) instacron:UFRN |
instname_str |
Universidade Federal do Rio Grande do Norte (UFRN) |
instacron_str |
UFRN |
institution |
UFRN |
reponame_str |
Repositório Institucional da UFRN |
collection |
Repositório Institucional da UFRN |
bitstream.url.fl_str_mv |
https://repositorio.ufrn.br/bitstream/123456789/46194/1/TelmisartanDecreasesInflammation_SILVA_2015.pdf https://repositorio.ufrn.br/bitstream/123456789/46194/2/license_rdf https://repositorio.ufrn.br/bitstream/123456789/46194/3/license.txt |
bitstream.checksum.fl_str_mv |
c7fd9496d72864eab4606db506b67a3c 4d2950bda3d176f570a9f8b328dfbbef e9597aa2854d128fd968be5edc8a28d9 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN) |
repository.mail.fl_str_mv |
|
_version_ |
1797776942184792064 |